The protective effect of oxygenated perfluorocarbons (PFCs) on intestinal ischemia reperfusion injury (I/R) in rabbits.
OBJECTIVE
To evaluate the effect of intraluminal administration of oxygenated perfluorocarbons (PFCs) on small intestine's viability in an experimental model of acute ischemia-reperfusion (I/R).


METHODS
Twenty rabbits were divided in four groups: sham-operated controls (group A), acute I/R (group B), acute I/R plus infusion of PFCs 30 min before ischemia (group C), and acute I/R plus infusion of PFCs 30 min before reperfusion (group D). Malondialdehyde (MDA) tissue levels and d-lactate blood samples were taken. All tissue sections were examined under light microscope.


RESULTS
Mean MDA levels in group A: 1.79 +/- 0.97 at 0 min, 2.25 +/- 1.76 at 120 min and 3.70 +/- 1.76 nmols/g at 180 min. Group B: 2.60 +/- 0.58 at 0 min, 4.20 +/- 0.58 at 120 min and 5.48 +/- 2.01 at 180 min. Group C: 1.54 +/- 0.85 at 0 min, 1.14 +/- 0.37 at 120 min and 0.59 +/- 0.35 at 180 min. Group D: 2.12 +/- 0.62 at 0 min, 3.97 +/- 0.70 at 120 min and 2.32 +/- 0.37 at 180 min (p < 0.05). Mean d-lactate levels in group A: at 0 min 36.45 +/- 1.99, at 120 min 39.10 +/- 2.37 and at 180 min 40.05 +/- 2.13 mg/dl. Group B: 61.23 +/- 11.03 at 0 min, 74.84 +/- 10.70 at 120 min and 89.90 +/- 9.29 at 180 min. Group C: at 0 min 51.05 +/- 10.36, at 120 min 56.07 +/- 11.27 and at 180 min 57.20 +/- 11.19. Group D: 64.36 +/- 5.26 at 0 min, 72.55 +/- 7.19 at 120 min and 77.02 +/- 9.41 at 180 min (p < 0.05). Histopathological analysis indicated a significant improvement in the groups of oxygenated PFCs compared with I/R group.


CONCLUSIONS
Intraluminal administration of oxygenated PFCs seems that protect the intestine from the I/R injury.
Ntinas
Achilleas
A
5th Surgery, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Iliadis
Stavros
S
Alvanou Achparaki
Athanasia
A
Vrochides
Dionisios
D
Pitoulias
Georgios
G
Papageorgiou
Georgios
G
Spyridis
Charalambos
C
Papadimitriou
Dimitrios
D
Karamanos
Dimitrios
D
Gerasimidis
Thomas
T
D000818:Animals; D002470:Cell Survival; D019610:Cytoprotection; D004195:Disease Models, Animal; D005466:Fluorocarbons / Q000008:administration & dosage*; D007263:Infusions, Parenteral; D007413:Intestinal Mucosa / Q000378:metabolism; D007422:Intestines / Q000098:blood supply* / Q000187:drug effects* / Q000473:pathology; D019344:Lactic Acid / Q000097:blood; D008315:Malondialdehyde / Q000378:metabolism; D010100:Oxygen / Q000008:administration & dosage*; D020011:Protective Agents / Q000008:administration & dosage*; D011817:Rabbits; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D013997:Time Factors
D005466:Fluorocarbons; D020011:Protective Agents; D019344:Lactic Acid; D008315:Malondialdehyde; D010100:Oxygen